{"doi":"10.1002/alz.14322","title":"Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults","abstract":"INTRODUCTION: The relationship between Alzheimer's disease (AD) plasma biomarkers, and physical functioning (PF) across diverse races and ethnicities remains unclear. This study aims to explore this association in an ethno-racially diverse sample of cognitively unimpaired community-dwelling adults. METHODS: Data clinical examinations, neuropsychological tests, blood draws, and PF exams (Timed Up and Go [TUG] and Short Physical Performance Battery [SPPB]) were analyzed. Multivariable linear regressions assessed the association between PF and AD plasma biomarkers (amyloid beta [Aβ]40, Aβ42, total tau [t-tau], neurofiliament light chain [NfL]). RESULTS: The sample (n = 2358; mean age 64.7 years; 65.9% female), was 20% African American, 41.9% non-Hispanic White, and 38.1% Hispanic. Findings indicate that worse PF is linked to higher biomarker levels (p < 0.05). Associations differed by race and ethnicity group. TUG time was associated (p < 0.05) with Aβ40, Aβ42, and tau among non-Hispanic Whites, whereas SPPB scores were associated (p < 0.05) with t-tau and NfL among African Americans. DISCUSSION: PF, ethnic/racial, and plasma AD biomarker data should be used to aid in developing risk profiles for neurodegenerative diseases. HIGHLIGHTS: Alzheimer's disease (AD) biomarkers are associated with physical functioning (PF) Ethno-racial variation exists in AD biomarker and PF associations Race and ethnicity should considered when assessing neurodegenerative disease risk.","journal":"Alzheimer s & Dementia","year":2025,"id":514133,"datarank":0.3657373521580206,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.03615366555758762,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.03615366555758762,"corpus_percentile":51.1564941595111,"corpus_rank":6315,"citation_count":8,"citer_count":8,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.7188,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":326972,"name":"James Hall","orcid":"0000-0002-8153-1537","position":1,"is_corresponding":false},{"id":633744,"name":"Stephanie Large","orcid":null,"position":2,"is_corresponding":false},{"id":1231522,"name":"Lubnaa Abdullah","orcid":"0000-0002-3664-1075","position":3,"is_corresponding":false},{"id":632832,"name":"Melissa Petersen","orcid":"0000-0002-3920-5877","position":4,"is_corresponding":false},{"id":414357,"name":"Leigh Johnson","orcid":"0000-0001-7769-8417","position":5,"is_corresponding":false},{"id":270462,"name":"Sid E. O’Bryant","orcid":"0000-0003-0582-5266","position":6,"is_corresponding":false},{"id":437798,"name":"Gregory Knell","orcid":"0000-0002-5067-544X","position":0,"is_corresponding":true}],"reference_count":70,"raw_metadata":null,"created_at":"2026-07-19T02:48:23.284782Z","pmid":"39744805","pmcid":"PMC11772697","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}